

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Glucose-Dependent Insulinotropic Polypeptide (GIP)/ Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Override(s)	Approval Duration
Prior Authorization	1 year

Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonists

Medications	Quantity Limit	Comments
Ozempic (semaglutide)	0.25 mg/dose, 0.5 mg/dose (2 mg prefilled pen): 1 prefilled pen per 28 days 1 mg/dose (4 mg prefilled pen): 1 prefilled pen (1 carton) per 28 days 2 mg/dose (8 mg prefilled pen): 1 prefilled pen (1 carton) per 28 days	Preferred
Rybelsus (semaglutide)	3 mg tablet: 1 carton (30 tablets) per one time fill 7 mg, 14 mg tablets: 1 carton (30 tablets) per 30 days	
Trulicity (dulaglutide)	4 prefilled pens/syringes per 28 days	
Victoza (liraglutide)	1 box per 30 days	

Adlyxin (lixisenatide)	Starter Pack: 1 pack (2 pens) per one time fill (28 day supply) Maintenance Pack: 1 pack (2 pens) per 28 days	Non-Preferred
Bydureon (exenatide extended release)	4 vials/prefilled pens per 28 days	
Bydureon BCise (exenatide extended release)	4 auto-injector pens per 28 days	
Byetta (exenatide)	1 prefilled pen per 30 days	

Glucose-Dependent Insulinotropic Polypeptide (GIP)/Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonists

Medications	Quantity Limit	Comments
Mounjaro (tirzepatide)	4 pens per 28 days	Preferred

APPROVAL CRITERIA

Requests for a preferred GLP-1 receptor agonist or GIP/GLP-1 receptor agonist may be approved when the following criteria are met:

- I. Individual meets one of the following:
 - A. Requesting Mounjaro and 18 years of age or older; **OR**
 - B. Requesting Trulicity or Victoza and 10 years of age or older; **OR**
 - C. Requesting Ozempic or Rybelsus and 18 years of age or older;

AND

- II. Individual has a diagnosis of type 2 diabetes;

AND

- III. Documentation is provided that diagnosis has been verified by history of:
 - A. Hemoglobin A1c (A1C) greater than or equal to 6.5%; **OR**
 - B. Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (after fasting for at least 8 hours); **OR**
 - C. 2 hour plasma glucose greater than or equal to 200 mg/dL as part of an oral glucose tolerance test (75 g oral glucose after fasting for at least 8 hours); **OR**

- D. Symptoms of hyperglycemia (including polyuria, polydipsia, polyphagia) and a random plasma glucose greater than or equal to 200 mg/dL;

AND

- IV. Individual has had a trial and inadequate response or intolerance to metformin (AACE 2023). Medication samples/coupons/discount cards are excluded from consideration as a trial.;

OR

- V. Individual has a contraindication to metformin therapy;

OR

- VI. If requesting Ozempic, Trulicity or Victoza, individual has a history of atherosclerotic cardiovascular disease (ASCVD) including one or more of the following:

- A. Acute coronary syndrome;
- B. Coronary artery disease (CAD);
- C. History of myocardial infarction (MI);
- D. Stable or unstable angina;
- E. Coronary or other arterial revascularization;
- F. Stroke;
- G. Transient ischemic attack (TIA);
- H. Peripheral arterial disease (PAD).

Requests for a non-preferred GLP-1 receptor agonist may be approved when the following criteria are met:

- I. Individual meets one of the following:
 - A. Requesting Bydureon/BCise and 10 years of age or older; **OR**
 - B. Requesting Adlyxin or Byetta and 18 years of age or older;

AND

- II. Individual has a diagnosis of type 2 diabetes;

AND

- III. Documentation is provided that diagnosis has been verified by history of:
 - A. Hemoglobin A1c (A1C) greater than or equal to 6.5%; **OR**
 - B. Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (after fasting for at least 8 hours); **OR**
 - C. 2 hour plasma glucose greater than or equal to 200 mg/dL as part of an oral glucose tolerance test (75 g oral glucose after fasting for at least 8 hours); **OR**
 - D. Symptoms of hyperglycemia (including polyuria, polydipsia, polyphagia) and a random plasma glucose greater than or equal to 200 mg/dL;

AND

- IV. One of the following:
- A. Individual has had a trial and inadequate response or intolerance to metformin (AACE 2023). Medication samples/coupons/discount cards are excluded from consideration as a trial.;
- OR**
- B. Individual has a contraindication to metformin therapy;

AND

- V. Documentation is provided that individual has had a trial and inadequate response or intolerance to two preferred agents. Medication samples/coupons/discount cards are excluded from consideration as a trial.

A GLP-1 receptor agonist or GIP/GLP-1 receptor agonist may not be approved for any of the following:

- I. Individual with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or a personal or family history of medullary thyroid carcinoma (MTC); **OR**
- II. Individual is requesting for treatment of type 1 diabetes; **OR**
- III. Individual is requesting for the treatment of prediabetes; **OR**
- IV. Individual is requesting for the treatment of obesity; **OR**
- V. Individual is requesting for weight loss; **OR**
- VI. Individual is requesting Bydureon/BCise (exenatide extended-release) with an eGFR less than 45 mL/min/1.73 m²; **OR**
- VII. Individual is requesting Byetta (exenatide) with an eGFR less than 30 mL/min/1.73 m²; **OR**
- VIII. Individual is using in combination with another GLP-1 receptor agonist (including but not limited to Saxenda, Wegovy, Soliqua or Xultophy); **OR**
- IX. Individual is using in combination with a DPP4 inhibitor (including but not limited to Janumet/XR, Januvia, Jentadueto/XR, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, Tradjenta, Glyxambi, Qtern, Steglujan or Trijardy XR).

Note:

Most of the GLP-1 receptor agonists and GIP/GLP-1 receptor agonists have a black box warning for risk of thyroid C-cell tumors. GLP-1 receptor agonists have been found to cause thyroid C-cell tumors at clinically relevant exposure in rats. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Most GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of MTC or in individuals with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Individuals using GLP-1 receptor agonists should be educated on the potential risk of MTC and symptoms of thyroid tumors.

Key References:

1. American Diabetes Association. Standard of Care in Diabetes – 2023. Available at: https://diabetesjournals.org/care/issue/46/Supplement_1 Accessed on March 9, 2023.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: May 10, 2023.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
5. Samson SL, Vellanki P, Blonde L, et. al. American Association of Clinical Endocrinologists (AACE) Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. *Endocrine Practice*. 2023;29:305-340.
6. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>. Accessed: May 9, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.